Transforming growth factor-β is involved in the pathogenesis of dialysis-related amyloidosis

Kidney International

Volumn 57, Issue 2, 2000, Pages 697-708

  Matsuo, Kenzo ^a,b   Ikizler, T Alp ^a,b   Hoover, Richard L ^a,b   Nakamoto, Masahiko ^a,b   Yasunaga, Chikao ^a,b   Pupim, Lara B ^a,b   Hakim, Raymond M ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Saiseikai Yahata Hospital   (Japan)

Author keywords

AGE 2m; Amyloidosis; Chemotaxis; Cytokines; Hemodialysis; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

AMYLOIDOSIS; ARTICLE; CELL CULTURE; CHEMOTAXIS; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DIALYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0033945966     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00892.x     Document Type: Article

References (44)

1. 1. DRUEKE TB: Beta-2-microglobulin amyloidosis and renal bone disease. Miner Electrolyte Metab 17:261-272, 1991
2. 2. KOCH KM: Dialysis-related amyloidosis [clinical conference]. Kidney Int 41:1416-1429, 1992
3. 3. GEJYO F, YAMADA T, ODANI S, NAKAGAWA Y, ARAKAWA M, KUNITOMO T, KATAOKA H, SUZUKI M, HIRASAWA Y, SHIRAHAMA T, COHEN AS, SCHMID K: A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 129:701-706, 1985
4. 4. MIYATA T, ODA O, INAGI R, IIDA Y, ARAKI N, YAMADA N, HORIUCHI S, TANIGUCHI N, MAEDA K, KINOSHITA T: Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
5. 5. NIWA T, MIYAZAKI S, KATSUZAKI T, TAKEMICHI N, TAKEI Y, MIYAZAKI T, MORITA, HIRASAWA N: Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 48:771-778, 1995
6. 6. MIYATA T, INAGI R, IIDA Y, SATO M, YAMADA N, ODA O, MAEDA K, SEO H: Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 93:521-528, 1994
7. 7. ROBERTS AB, THOMPSON NL, HEINE U, FLANDERS C, SPORN MB: Transforming growth factor-beta: Possible roles in carcinogenesis. Br J Cancer 57:594-600, 1988
8. 8. MASSAGUE J: The transforming growth factor-beta family. Annu Rev Cell Biol 6:597-641, 1990
9. 9. ROBERTS AB, SPORN MB: Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 8:1-9, 1993
10. 10. WAHL SM, MCCARTNEY-FRANCIS N, MERGENHAGEN SE: Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today 10:258-261, 1989
11. 11. WAHL SM, HUNT DA, WAKEFIELD LM, MCCARTNEY-FRANCIS N, WAHL LM, ROBERTS AB, SPORN MB: Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84:5788-5792, 1987
12. 12. WISEMAN DM, POLVERINI PJ, KAMP DW, LEIBOVICH SJ: Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 157:793-800, 1988
13. 13. BRANDES ME, MAI UE, OHURA K, WAHL SM: Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol 147:1600-1606, 1991
14. 14. REIBMAN J, MEIXLER S, LEE TC, GOLD LI, CRONSTEIN BN, HAINES KA, KOLASINSKI SL, WEISSMANN G: Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci USA 88:6805-6809, 1991
15. 15. GRUBER BL, MARCHESE MJ, KEW RR: Transforming growth factor-beta 1 mediates mast cell chemotaxis. J Immunol 152:5860-5867, 1994
16. 16. WAHL SM: Transforming growth factor beta (TGF-beta) in inflammation: A cause and a cure. J Clin Immunol 12:61-74, 1992
17. 17. CHANTRY D, TURNER M, ABNEY E, FELDMANN M: Modulation of cytokine production by transforming growth factor-beta. J Immunol 142:4295-4300, 1989
18. 18. MCCARTNEY-FRANCIS N, MIZEL D, WONG H, WAHL L, WAHL S: TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes. Growth Factors 4:27-35, 1990
19. 19. DUBOIS CM, RUSCETTI FW, PALASZYNSKI EW, FALK LA, OPPENHEIM JJ, KELLER JR: Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: Proposed mechanism of inhibition of IL-1 action. J Exp Med 172:737-744, 1990
20. 20. TURNER M, CHANTRY D, KATSIKIS P, BERGER A, BRENNAN FM, FELDMANN M: Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol 21:1635-1639, 1991
21. 21. WAHL SM, COSTA GL, CORCORAN M, WAHL LM, BERGER AE: Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 150:3553-3560, 1993
22. 22. TSUNAWAKI S, SPORN M, DING A, NATHAN C: Deactivation of macrophages by transforming growth factor-beta. Nature 334:260-262, 1988
23. 23. DING A, NATHAN CF, GRAYCAR J, DERYNCK R, STUEHR DJ, SRIMAL S: Macrophage deactivating factor and transforming growth factors-beta 1, -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 145:940-944, 1990
24. 24. NELSON BJ, RALPH P, GREEN SJ, NACY CA: Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol 146:1849-1857, 1991
25. 25. ESPEVIK T, FIGARI IS, SHALABY MR, LACKIDES GA, LEWIS GD, SHEPARD HM, PALLADINO MA JR: Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 166:571-576, 1987
26. 26. BOGDAN C, PAIK J, VODOVOTZ Y, NATHAN C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem 267:23301-23308, 1992
27. 27. VLASSARA H, BROWNLEE M, CERAMI A: High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588-5592, 1985
28. 28. MIYATA T, IIDA Y, UEDA Y, SHINZATO T, SEO H, MONNIER VM, MAEDA K, WADA Y: Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Kidney Int 49:538-550, 1996
29. 29. TREVES AJ, YAGODA D, HAIMOVITZ A, RAMU N, RACHMILEWITZ D. FUKS Z: The isolation and purification of human peripheral blood monocytes in cell suspension. J Immunol Methods 39:71-80, 1980
30. 30. EHLERDING G, SCHAEFFER J, DROMMER W, MIYATA T, KOCH KM, FLOEGE J: Alterations of synovial tissue and their potential role in the deposition of β2-microglobulin-associated amyloid. Nephrol Dial Transplant 13:1465-1475, 1998
31. 31. VLASSARA H, BROWNLEE M, MANOGUE KR, DINARELLO CA, PASAGIAN A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role of normal tissue remodeling. Science 240:1546-1548, 1988
32. 32. JANSON RW, HANCE KR, AREND WP: Production of IL-1 receptor antagonist by human in vitro-derived macrophages. J Immunol 147:4218-4223, 1991
33. 33. HOU FF, CHERTOW GM, KAY J, BOYCE J, LAZARUS JM, BRAATZ JA, OWEN WF JR: The interaction between β2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 51:1514-1519, 1997
34. 34. FRANZEN P, TEN DIJKE P, ICHIJO H, YAMASHITA H, SCHULZ P, HELDIN CH, MIYAZONO K: Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 75:681-692, 1993
35. 35. JANSON RW, JOSLIN FG, AREND WP: The effects of differentiating agents on IL-1 beta production in cultured human monocytes. J Immunol 145:2161-2166, 1990
36. 36. WEWERS MD, RENNARD SI, HANCE AJ, BITTERMAN PB, CRYSTAL RG: Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1. J Clin Invest 74:2208-2218, 1984
37. 37. BECKER S, JOHNSON C, HALME J, HASKILL S: Interleukin-1 production and antigen presentation by normal human peritoneal macrophages. Cell Immunol 98:467-476, 1986
38. 38. MIYATA T, HORI O, ZHANG J, YAN SD, FERRAN L, IIDA Y, SCHMIDT AM: The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094, 1996
39. 39. ANDERSON J, BRIEFEL G, JONES JM, RYU JH, MCGUIRE M, YUN YP: Effects of acetate dialysate on transforming growth factor beta 1, interleukin, and beta 2-microglobulin plasma levels. Kidney Int 40:1110-1117, 1991
40. 40. MEGF JL, CAPO C, PURGUS R, OLMER M: Monocyte production of transforming growth factor beta in long-term hemodialysis: Modulation by hemodialysis membranes. Am J Kidney Dis 28:395-399, 1996
41. 41. SUTHANTHIRAN M, KHANNA A, CUKRAN D, ADHIKARLA R, SHARMA VK, SINGH T, AUGUST P: Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 53:639-644, 1998
42. 42. MCCAFFREY TA, FALCONE DJ, BRAYTON CF, AGARWAL LA, WELT FG, WEKSLFR BB: Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol 109:441-448, 1989
43. 43. MCCAFFREY TA, FALCONE DJ, VICENTE D, DU B, CONSIGLI S, BORTH W: Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol 159:51-59, 1994
44. 44. MAJDALANI G, CHOMANT J, KACHKO A, YANAI M, MAN NK: Kinetics of technetium-labeled heparin in hemodialyzed patients. Kidney Int Suppl 41:S131-S134, 1993